SEC Comment Letter for Viatris Inc (VTRS) (CIK 0001792044) (VTRS) — Jul 27, 2022
Viatris Inc (VTRS) (CIK 0001792044)
Date: July 27, 2022 · CIK: 0001792044 · Accession: 0000000000-22-007905
AI Filing Summary & Sentiment
File numbers found in text: 001-39695
Letter
United States securities and exchange commission logo July 27, 2022 Sanjeev Narula Chief Financial Officer Viatris Inc 1000 Mylan Boulevard Canonsburg, PA 15317 Re:Viatris Inc Form 10-K for the Fiscal Year Ended December 31, 2021 Filed February 28, 2022 Form 10-Q for the Quarterly Period ended March 31, 2022 Filed May 9, 2022 File No. 001-39695 Dear Mr. Narula: We have limited our review of your filing to the financial statements and related disclosures and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response. After reviewing your response to this comment, we may have additional comments. Form 10-Q for the quarterly period ended March 31, 2022 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Results of Operations Total Revenues, page 48 1.You disclose that the decrease in total revenues and net sales was primarily driven by a decrease of approximately $169.7 million in net sales from existing products as a result of lower pricing and volumes. Please provide us with proposed disclosure to be included in future periodic reports that quantifies the impact of price and volume separately. Alternatively, we note in your first quarter 2022 earnings presentation that you quantify the decrease in net sales due to competition on key US products and other base business erosion separately. Please refer to Item 303(a)(3)(iii) of Regulation S-K.
FirstName LastNameSanjeev Narula Comapany NameViatris Inc July 27, 2022 Page 2 FirstName LastName Sanjeev Narula Viatris Inc July 27, 2022 Page 2 In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. You may contact Vanessa Robertson at 202-551-3649 or Kevin Vaughn at 202-551-3494 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
July 27, 2022
Sanjeev Narula
Chief Financial Officer
Viatris Inc
1000 Mylan Boulevard
Canonsburg, PA 15317
Re:Viatris Inc
Form 10-K for the Fiscal Year Ended December 31, 2021
Filed February 28, 2022
Form 10-Q for the Quarterly Period ended March 31, 2022
Filed May 9, 2022
File No. 001-39695
Dear Mr. Narula:
We have limited our review of your filing to the financial statements and related
disclosures and have the following comment. In our comment, we may ask you to provide us
with information so we may better understand your disclosure.
Please respond to this comment within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comments apply to your facts and circumstances, please tell us why in your response.
After reviewing your response to this comment, we may have additional comments.
Form 10-Q for the quarterly period ended March 31, 2022
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Results of Operations
Total Revenues, page 48
1.You disclose that the decrease in total revenues and net sales was primarily driven by a
decrease of approximately $169.7 million in net sales from existing products as a result of
lower pricing and volumes. Please provide us with proposed disclosure to be included in
future periodic reports that quantifies the impact of price and volume separately.
Alternatively, we note in your first quarter 2022 earnings presentation that you quantify
the decrease in net sales due to competition on key US products and other base business
erosion separately. Please refer to Item 303(a)(3)(iii) of Regulation S-K.
FirstName LastNameSanjeev Narula
Comapany NameViatris Inc
July 27, 2022 Page 2
FirstName LastName
Sanjeev Narula
Viatris Inc
July 27, 2022
Page 2
In closing, we remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
You may contact Vanessa Robertson at 202-551-3649 or Kevin Vaughn at 202-551-3494
with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences